Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy...( - New antiepileptic drug with novel m...),Health

- New antiepileptic drug with novel mechanism of action helps address critical unmet medical need for many people living with uncontrolled epilepsy

- Vimpat(R) offers hope to people with epilepsy who still have uncontrolled partial onset seizures with current treatment

ATLANTA, May 26 /PRNewswire/ -- press release, regulated information - UCB today announced that Vimpat(R) (lacosamide) C-V, a new antiepileptic drug (AED) is available in the U.S. as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are 17 years and older. Vimpat(R) will be available in U.S. pharmacies by the first week of June 2009.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/vimpat/34012/

"The availability of Vimpat(R) in the U.S. is an important milestone for people living with epilepsy and for UCB," said Rich Denness, Vice-President and General Manager CNS U.S., UCB. "Bringing Vimpat(R) to U.S. patients underscores UCB's commitment to the epilepsy community and UCB's leadership position in this disease state."

Epilepsy affects approximately 6 million people in the U.S., Japan, U.K., France, Germany, Italy and Spain, and it can strike anyone at anytime.

"Vimpat(R) provides new hope in helping patients move closer to the goal of seizure freedom," said Steven S. Chung, MD, Director of Clinical Epilepsy Research at Barrow Neurological Institute in Phoenix. "Vimpat(R) can help patients across the treatment paradigm, from those recently diagnosed who have not achieved seizure control on current therapy, to those who have tried a variety of medications and are still suffering from frequent seizures."

The unmet medical need

Epilepsy is a common neurological disorder that can be life long, and is difficult to control with
'/>"/>